HK1202800A1 - Therapeutic uses of fibroblast growth factor 21 proteins 21 - Google Patents

Therapeutic uses of fibroblast growth factor 21 proteins 21

Info

Publication number
HK1202800A1
HK1202800A1 HK15103356.5A HK15103356A HK1202800A1 HK 1202800 A1 HK1202800 A1 HK 1202800A1 HK 15103356 A HK15103356 A HK 15103356A HK 1202800 A1 HK1202800 A1 HK 1202800A1
Authority
HK
Hong Kong
Prior art keywords
proteins
growth factor
fibroblast growth
therapeutic uses
therapeutic
Prior art date
Application number
HK15103356.5A
Other languages
English (en)
Chinese (zh)
Inventor
Yanfei Linda Ma
Rovira Armando Rafael Irizarry
Vincent Louis Reynolds
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1202800(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1202800A1 publication Critical patent/HK1202800A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15103356.5A 2012-05-15 2015-04-02 Therapeutic uses of fibroblast growth factor 21 proteins 21 HK1202800A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261646974P 2012-05-15 2012-05-15
US201361786939P 2013-03-15 2013-03-15
PCT/US2013/040275 WO2013173158A1 (en) 2012-05-15 2013-05-09 Therapeutic uses of fibroblast growth factor 21 proteins

Publications (1)

Publication Number Publication Date
HK1202800A1 true HK1202800A1 (en) 2015-10-09

Family

ID=48483225

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103356.5A HK1202800A1 (en) 2012-05-15 2015-04-02 Therapeutic uses of fibroblast growth factor 21 proteins 21

Country Status (21)

Country Link
US (1) US20150141335A1 (he)
EP (1) EP2852398A1 (he)
JP (1) JP2015522539A (he)
KR (1) KR20150002801A (he)
CN (1) CN104302311A (he)
AU (1) AU2013263188A1 (he)
BR (1) BR112014028413A2 (he)
CA (1) CA2869320A1 (he)
CL (1) CL2014002846A1 (he)
CO (1) CO7131381A2 (he)
EA (1) EA201491856A1 (he)
HK (1) HK1202800A1 (he)
IL (1) IL235482A0 (he)
MA (1) MA37506B1 (he)
MX (1) MX2014013913A (he)
PE (1) PE20142432A1 (he)
PH (1) PH12014502537A1 (he)
SG (1) SG11201407655TA (he)
TN (1) TN2014000409A1 (he)
WO (1) WO2013173158A1 (he)
ZA (1) ZA201407532B (he)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2726511T3 (pl) 2011-07-01 2019-12-31 Ngm Biopharmaceuticals, Inc. Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP2938740B1 (en) 2012-12-27 2022-04-20 NGM Biopharmaceuticals, Inc. Chimeric fgf19 peptides for use in treating bile acid disorders
MX2016004822A (es) 2013-10-28 2016-08-17 Ngm Biopharmaceuticals Inc Modelos de cancer y metodos asociados.
HUE050279T2 (hu) 2014-01-24 2020-11-30 Ngm Biopharmaceuticals Inc Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10293026B2 (en) 2014-09-08 2019-05-21 Osaka University Agent for preventing or treating demyelinating disease
IL251834B2 (he) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc הרכבים רוקחים המכילים וריאנטים של פפטיד ושיטות לשימוש בהם
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
ES2871036T3 (es) 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523084A (ja) * 2007-03-30 2010-07-15 アンブルックス,インコーポレイテッド 修飾fgf−21ポリペプチド
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos

Also Published As

Publication number Publication date
CO7131381A2 (es) 2014-12-01
CL2014002846A1 (es) 2015-01-30
MA37506A1 (fr) 2016-01-29
MA37506B1 (fr) 2017-03-31
AU2013263188A1 (en) 2014-10-16
TN2014000409A1 (en) 2015-12-21
CN104302311A (zh) 2015-01-21
BR112014028413A2 (pt) 2017-11-07
ZA201407532B (en) 2016-05-25
IL235482A0 (he) 2014-12-31
PE20142432A1 (es) 2015-01-22
CA2869320A1 (en) 2013-11-21
JP2015522539A (ja) 2015-08-06
US20150141335A1 (en) 2015-05-21
SG11201407655TA (en) 2014-12-30
PH12014502537A1 (en) 2015-01-21
EP2852398A1 (en) 2015-04-01
KR20150002801A (ko) 2015-01-07
EA201491856A1 (ru) 2015-03-31
MX2014013913A (es) 2015-02-17
WO2013173158A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
HK1202800A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins 21
HK1203357A1 (en) Fibroblast growth factor 21 proteins 21
HK1211607A1 (en) Chimeric fibroblast growth factor 21 proteins and methods of use 21
HK1219964A1 (zh) 治療性蛋白藥物物質的整合連續製造
ZA201407938B (en) Fibroblast growth factor 21 variants
IL279676A (he) חלבונים רקומביננטים ושימושים טיפוליים
HK1206023A1 (en) Inhibitors of the fibroblast growth factor receptor
HK1206639A1 (en) In vivo production of proteins
CO6910165A2 (es) Variantes del factor 21 del crecimiento de fibroblastos
HK1212382A1 (en) Differentiation of human fibroblast cells
EP2716653A4 (en) PROTEIN L1 TRUNCATED FROM HUMAN PAPILLOMAVIRUS TYPE 33
HK1211789A1 (en) Plants for production of therapeutic proteins
IL238775A0 (he) ניקוי של גלקטוסרבריסידז ביטא גלקטוסידאז רקוביננטי הומני
EP3560952C0 (en) VARIANT OF BPIFB4 PROTEIN
EP2925341A4 (en) PEPTIDE COMPOUNDS AND METHODS OF MAKING AND USING THEM
HK1205147A1 (en) Truncated l1 proteins of human papillomavirus type 45 45 l1
SI2555790T1 (sl) Terapevtska uporaba proteina beta2-mikroglobulina